Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Hymecromone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hymecromone is under development for the treatment of pulmonary hypertension (PH) including interstitial lung disease and primary sclerosing cholangitis. It is administered by oral route. The drug candidate acts by targeting hyaluronan. It was also under development for type I diabetes.
Halo Biosciences overview
Halo Biosciences is centered around making first-in-class, illness changing treatments utilizing creative ways to deal with alter the extracellular lattice (ECM). It is headquartered in Stanford, California, the US.
For a complete picture of Hymecromone’s drug-specific PTSR and LoA scores, buy the report here.